EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A New Hope for Woman with Vasomotor Symptoms: Neurokinin B Antagonists

Blazej Meczekalski, Anna Kostrzak, Christian Unogu, Stefania Bochynska, Marzena Maciejewska-Jeske, Gregory Bala iD, Anna Szeliga

Journal of Clinical Medicine · 21.02.2025 · 14 (5) · 1438

DOI: 10.3390/jcm14051438 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.02.2025. Verfasst von Blazej Meczekalski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 60-535 Poznan, Poland. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KNDy (kisspeptine, neurokinin B, dynorphin) neurons, located in the hypothalamus, play a crucial role in the development of vasomotor symptoms (VSM) in menopausal women. Estrogen withdrawal during menopause leads to the hyperactivation of kisspeptin and neurokinin B (NKB) secretion, contributing to the onset of these symptoms. The identification of NKB/neurokinin B receptor (NK3R) signaling as a key mechanism in menopausal hot flashes has driven the development of NK3R antagonists. These antagonists restore the disrupted balance in KNDy neuron activity caused by estrogen deficiency, thereby reducing the frequency and severity of VMS. In 2023, the FDA approved fezolinetant, the first selective NK3R antagonist, for the treatment of moderate to severe VMS associated with menopause. Additionally, elinzanetant, a dual neurokinin-1 and neurokinin-3 receptor antagonist, has demonstrated promising results. The approval application for elinzanetant was supported by positive findings from the OASIS 1, 2, and 3 Phase III clinical studies. The dual antagonism of NK-1 and NK-3 receptors enhances its efficacy by alleviating menopause-related sleep disturbances and modulating peripheral vasodilatation. In this regard, elinzanetant represents a promising non-hormonal treatment that targets the underlying causes of VMS through NK-1 and NK-3 receptor pathways. The development of neurokinin B antagonist for VMS treatment exemplifies the impact of advanced pharmacological research on gynecological endocrinology.

Schlagwörter

Stichwörter der Autor:innen

NKBelinzanetantfezolinetantmenopauseneurokinin Bvasomotor symptoms

Autor:innen und Institutionen

  • Department of Gynecological Endocrinology, Poznan University of Medical Sciences, 60-535 Poznan, Poland.
  • UCD School of Medicine, University College Dublin, D04 V1W8 Dublin, Ireland.

ORCID-Profile: Gregory Bala

Zitieren

APA

Meczekalski, B., Kostrzak, A., Unogu, C., Bochynska, S., Maciejewska-Jeske, M., Bala, G., & Szeliga, A. (2025). A New Hope for Woman with Vasomotor Symptoms: Neurokinin B Antagonists. Journal of Clinical Medicine, 14(5), 1438. https://doi.org/10.3390/jcm14051438

Vancouver

Meczekalski B, Kostrzak A, Unogu C, Bochynska S, Maciejewska-Jeske M, Bala G, et al. A New Hope for Woman with Vasomotor Symptoms: Neurokinin B Antagonists. Journal of Clinical Medicine. 2025;14(5):1438. doi:10.3390/jcm14051438

BibTeX
@article{Meczekalski2025,
  author = {Meczekalski, Blazej and Kostrzak, Anna and Unogu, Christian and Bochynska, Stefania and Maciejewska-Jeske, Marzena and Bala, Gregory and Szeliga, Anna},
  title = {A New Hope for Woman with Vasomotor Symptoms: Neurokinin B Antagonists},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {5},
  pages = {1438},
  doi = {10.3390/jcm14051438}
}
Kostenlos starten →